Metride 4mg/500mg Tablet is a combination oral hypoglycemic agent containing Glimepiride 4mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, improves insulin sensitivity by decreasing hepatic glucose production and enhancing peripheral glucose uptake and utilization. The synergistic action of these two agents provides effective glycemic control in patients inadequately managed by diet and exercise alone. Metride is typically prescribed when monotherapy with either agent is insufficient. It is important to monitor blood glucose levels regularly to adjust dosage and minimize the risk of hypoglycemia, a potential side effect primarily associated with Glimepiride. Metformin’s common adverse effects include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, which often subside with continued use. Metride is contraindicated in patients with severe renal impairment, metabolic acidosis, or hypersensitivity to its components. Prior to initiation, renal function assessment is recommended. This combination therapy should be used as part of a comprehensive diabetes management plan, including diet, exercise, and regular monitoring of glycemic parameters to reduce the risk of diabetes-related complications.